Irlab Parkinson's Pact With Ipsen Up In The Air
Setback For Mesdopetam In Mid-Stage Study
The Swedish firm’s Parkinson's disease drug has failed to hit its primary endpoint in a Phase IIb study but Irlab believes that positive results on secondary goals merit further development of mesdopetam.
You may also be interested in...
Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment
The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.
Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.
Systems Biology In CNS: Mixed Results For IRLAB's Dyskinesia Candidate
A novel systems biology/network pharmacology approach to drug discovery in Parkinson’s disease is encouraging despite puzzling divergence in efficacy measures.